Evasc is pleased to be present at the following conferences and events in 2022. If you would like to set up a meeting to discuss your neurovascular requirements, please get in touch with us.
We're excited to announce the 1 year results from the European eCLIPs Safety, Feasibility, and Efficacy Study (EESIS).
We’re delighted to announce the enrolment of the first patient in Evasc Neurovascular’s French eCLIPs Safety, Feasibility, and Efficacy Study (EESIS-FR).
We are currently looking for a Quality Systems/Quality Assurance Coordinator to support our regulatory affairs, manufacturing and engineering teams while maintaining the effective operation of Evasc’s Quality Management System.
Evasc Neurovascular is proud to announce the third generation of its eCLIPs™ device, the eCLIPs Bifurcation Flow Diverter.
The eCLIPs device is the first neuro device that has gained Forfait Innovation approval and funding...
Robert was previously the Chief Technology Officer and Co-Founder at MicroVention Inc...
A new generation of eCLIPs implant, the eCLIPs bifurcation flow diverter (eBFD), with higher metal coverage showed similar reduction of flow in a bifurcation anatomy...
Evasc announces that the new eCLIPs Bifurcation Remodeling System (eB) has been granted CE Mark approval...
Dr. Rothman is an experienced executive who brings his expertise as founder, Director and investor...
NeuroNews interviewed Dr. Leif Sorensen to get his clinical experience with the 1st generation eCLIPs bifurcation system...
Wide necked bifurcation aneurysms(WNBA) are among the most difficult aneurysms to treat...